Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2024Health Economics ReviewOpen Access

Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China

View Full Paper
Ask AI
Bookmark
Share

Authors

SXShitong XieYSYanan ShengLCLing‐Hsiang Chuang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Xie et al. (2024) studied this question.

synapsesocial.com/papers/68e65d1eb6db6435875ebd2ehttps://doi.org/10.1186/s13561-024-00514-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma2021 · 19 citations
  2. 2Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma2015 · 15 citations
  3. 3Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma2015 · 17 citations
  4. 4Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma2014 · 38 citations
  5. 5Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma2007 · 237 citations